Neuralink Alums' Science Corp Raises $230M Series C at $1.5B Valuation to Advance Brain-Computer Interfaces and Retina Implants

Science Corp, a cutting-edge braintech startup, has secured $230 million in a Series C funding round, achieving a $1.5 billion valuation.

Led by Lightspeed Venture Partners with participation from Khosla Ventures, Y Combinator, IQT, and Quiet Capital, this brings the company's total funding to $489 million since its 2021 founding.

Neuralink Veterans at the Helm

Co-founded by Neuralink co-founder Max Hodak and ex-Neuralink leader Alan Mardinly, Science Corp leverages proven expertise in brain-computer interfaces.

Following a $104 million convertible note led by Khosla Ventures earlier this year, the latest raise underscores surging investor confidence in the team's vision.

Breakthrough Technologies

The Alameda-based firm is pioneering a brain-implant system alongside the PRIMA BCI retina implant to combat debilitating eye diseases.

By acquiring a MEMS manufacturing facility in North Carolina, Science Corp enables in-house production of neural chips, slashing costs and accelerating innovation over rivals reliant on outsourcing.

Intense Braintech Competition

In a sector attracting billions, Science Corp vies with Elon Musk's Neuralink, which clinched $650 million in Series E funding last year.

Global peers like China's Stairway Medical and Paradromics further highlight the high-stakes race to deliver transformative neural therapies.

Transformative Future Ahead

The infusion will fast-track PRIMA BCI commercialization and broaden clinical trials to include Stargardt disease and retinitis pigmentosa.

Ultimately, Science Corp's advancements promise to restore vision and redefine neurological treatments, impacting millions worldwide.